ArticleJournal of managed care & specialty pharmacy2026
Trends in use of continuous glucose monitors among individuals with type 2 diabetes enrolled in Medicare Advantage (2021-2023).
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2023, the Centers for Medicare and Medicaid Services (CMS) expanded continuous glucose monitoring (CGM) coverage in Medicare among individuals with type 2 diabetes and insulin use; however, little is known about current trends in CGM use among Medicare beneficiaries with type 2 diabetes.
objectiveTo assess trends in CGM use among Medicare beneficiaries with type 2 diabetes from 2021 to 2023 and to compare demographic and clinical characteristics of beneficiaries who used CGMs to those who did not in 2023.
methodsThis was a retrospective, repeated cross-sectional analysis. Using data from a large national Medicare Advantage (MA) plan, we described CGM use among MA beneficiaries with type 2 diabetes and evidence of insulin use to assess monthly trends in use from 2021 to 2023 and, using only 2023 data, examined characteristics of beneficiaries using CGMs.
resultsWe found that the prevalence of CGM use among MA beneficiaries with type 2 diabetes and insulin use increased from 1.4% in January 2021 to 17.2% in December 2023. Among the 2023 cohort, CGM users compared with nonusers had more primary care physician (PCP) visits and a higher likelihood of having a visit with an endocrinologist. CGM users were more clinically complex (ie, exhibiting higher clinical risk scores using the Deyo-Charlson Comorbidity Index and the Diabetes Complications Severity Index), more likely to have visits with both PCPs and endocrinologists, and more likely to be younger, be White, be with a disability, and live in rural areas.
conclusionsCGM utilization in an MA population increased concurrent with the expanded clinical guideline changes and Medicare coverage, though certain types of beneficiaries were more likely to use CGMs than others in 2023. Awareness of the differences in uptake of CGMs among beneficiaries could aid future education and outreach opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.